| Literature DB >> 31971308 |
Qi Wang1,2, Ming Yang1,3, Chi Wang1, Jiayue Cui1,4, Xinjun Li1, Chengbin Wang1.
Abstract
BACKGROUND: The role of serum cytokines/chemokines in early diagnosis of fungal infections has not been clearly clarified yet. This study aims to measure the serum levels of cytokines/chemokines in cases of fungemia and to compare them with culture-negative controls.Entities:
Keywords: biomarkers; chemokine; cytokine; fungemia
Mesh:
Substances:
Year: 2020 PMID: 31971308 PMCID: PMC7171303 DOI: 10.1002/jcla.23149
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
Demographical and clinical characteristics of enrolled patients
| Fungemia (n = 41) | Non‐fungemia (n = 54) |
| |
|---|---|---|---|
| Age (y) | 58.63 ± 21.97 | 63.78 ± 19.11 | NS |
| Male/Female | 16/25 | 33/21 | <.05 |
| Primary diagnosis [n (%)] | |||
| Leukemia or non‐Hodgkin's lymphoma | 2 (4.9%) | 1 (1.8%) | NS |
| Pancreatitis or pancreatic lesions | 8 (19.5%) | 2 (3.5%) | <.05 |
| Urinary system infections | 4 (9.6%) | 2 (3.7%) | <.05 |
| Cardiovascular system disease | 7 (17.1%) | 3 (5.6%) | <.05 |
| Obstructive jaundice or Biliary tract infection | 3 (7.3%) | 3 (5.6%) | NS |
| Hepatic disease | 2 (4.9%) | 1 (1.8%) | NS |
| Intestinal obstruction | 2 (4.9%) | 0 | <.05 |
| Abdominal pain or related symptoms | 2 (4.9%) | 2 (3.7%) | NS |
| Cancer | 5 (12.2%) | 2 (3.7%) | NS |
| Nervous system disease | 2 (4.9%) | 1 (1.9%) | NS |
| Musculoskeletal system disease | 2 (4.9%) | 1 (1.9%) | NS |
| Respiratory system disease | 1 (2.4%) | 24 (44.4%) | <.01 |
| Immune system disease | 0 | 2 (3.7%) | NS |
| Impetigo | 0 | 1 (1.9%) | NS |
| Infection of parapharyngeal space | 0 | 1 (1.9%) | NS |
| Trauma | 0 | 1 (1.9%) | NS |
| Fever or sepsis or shock | 1 (2.4%) | 10 (17.5%) | <.01 |
Indicates a significant statistical difference compared with the non‐fungemia group (P < .05).
Indicates a significant statistical difference compared with the non‐fungemia group (P < .01).
Microbiological distribution of the fungemia groups
| Causative pathogens | Patients, n (%) |
|---|---|
| Total | 41 |
| Candida albicans | 14 (34.1%) |
| Candida glabrata | 11 (26.8%) |
| Candida tropicalis | 8 (19.5%) |
| Candida parapsilosis | 7 (17.1%) |
| Trichosporonsis | 1 (2.4%) |
Comparison of laboratory parameters between fungemia and culture‐negative groups
| WBC (109/L) | N | L | NLR | CRP (mg/dL) | PCT (ng/mL) | |
|---|---|---|---|---|---|---|
| Fungemia | 10.46 ± 7.37 | 0.84 ± 0.10 | 0.10 ± 0.08 | 8.86 ± 14.79 | 11.31 ± 6.86 | 1.04 ± 9.81 |
| Non‐fungemia | 9.28 ± 7.11 | 0.80 ± 0.11 | 0.13 ± 0.08 | 9.15 ± 10.19 | 7.90 ± 6.44 | 0.34 ± 2.86 |
Abbreviations: CRP, C‐reactive protein; L, percentage of lymphocyte; N, percentage of neutrophil; NLR, ratio of neutrophil/lymphocyte; PCT, procalcitonin; WBC, white blood cell.
Indicates a significant statistical difference compared with culture‐negative group (P < .05).
Data were presented as median ± interquartile range.
Comparison of serum cytokine levels between the fungemia group and the negative control group
| Fungemia | Culture‐negative |
| |
|---|---|---|---|
| IFN‐γ, pg/mL, median (interq. interval) | 25.53 (8.40‐221.57) | 6.47 (2.945‐21.91) | .000 |
| G‐CSF, pg/mL, median (interq. interval) | 70.55 (40.6‐218.96) | 52.19 (30.57‐114.12) | .168 |
| TNF‐α, pg/mL, median (interq. interval) | 54.18 (34.67‐96.14) | 23.33 (14.7‐39.34) | .000 |
| MIP‐1β, pg/mL, median (interq. interval) | 90.72 (59.35‐150.49) | 50.56 (35.78‐65.63) | .000 |
| RANTES, pg/mL, median (interq. interval) | 21332.0 (7185‐58889) | 19825.5 (6328.6‐45099) | .674 |
| IL‐1β, pg/mL, median (interq. interval) | 2.35 (1.55‐4.93) | 3.15 (1.44‐5.41) | .400 |
| IL‐2, pg/mL, median (interq. interval) | 2.38 (1.41‐5.15) | 2.18 (1.27‐3.03) | .301 |
| IL‐3, pg/mL, median (interq. interval) | 0.93 (0.49‐1.61) | 1.1 (0.55‐2.10) | .626 |
| IL‐4, pg/mL, median (interq. interval) | 18.6 (10.96‐34.46) | 14.43 (9.17‐25.49) | .191 |
| IL‐6, pg/mL, median (interq. interval) | 85.52 (25.64‐247.46) | 41.11 (12.17‐25.48) | .045 |
| IL‐8, pg/mL, median (interq. interval) | 67.09 (38.34‐147.22) | 38.58 (12.17‐71.67) | .002 |
| IL‐10, pg/mL, median (interq. interval) | 144.47 (53.68‐456.48) | 17.05 (5.64‐49.93) | .000 |
| IL12p70, pg/mL, median (interq. interval) | 6.60 (2.53‐13.71) | 3.09 (1.11‐4.54) | .004 |
| IL17, pg/mL, median (interq. interval) | 6.38 (3.62‐16.96) | 2.90 (1.84‐4.54) | .000 |
P < .05.
P < .01.
P < .001.
Diagnostic parameters of cytokines and chemokines for fungemia
| Sensitivity (%) | Specificity (%) | Cutoff (pg/mL) | AUROC (95% CI) | |
|---|---|---|---|---|
| IFN‐γ | 66.7 | 72.2 | 22.195 | 0.719 (0.589‐0.849) |
| TNF‐α | 81.5 | 64.1 | 34.455 | 0.753 (0.631‐0.874) |
| MIP‐1β | 77.8 | 79.4 | 61.82 | 0.738 (0.613‐0.863) |
| IL‐6 | 96.3 | 25 | 12.11 | 0.574 (0.427‐0.712) |
| IL‐8 | 66.7 | 66.7 | 56.275 | 0.671 (0.544‐0.816) |
| IL‐10 | 77.8 | 75 | 51.525 | 0.792 (0.651‐0.889) |
| IL12p70 | 66.7 | 69.4 | 6.13 | 0.717 (0.589‐0.845) |
| IL‐17 | 81.5 | 63.9 | 3.445 | 0.773 (0.646‐0.879) |
| CRP | 66.7 | 71.1 | 8.575 | 0.655 (0.556‐0.817) |
| PCT | 88.9 | 47.2 | 0.3035 | 0.699 (0.571‐0.827) |
| MIP‐1β + IL‐17 | 81 | 81.5 | ‐ | 0.863 (0.787‐0.939) |
Abbreviations: AUROC, area under the receiver operating characteristic.
Unit for CRP is mg/dL.
Unit for PCT is ng/mL.
Logistic model parameter estimates and odds ratios
| Cytokine | Estimates | SE | Wald |
| OR | 95% CI |
|---|---|---|---|---|---|---|
| IFN‐γ | 0.009 | 0.005 | 3.671 | .055 | 1.009 | 1.000‐1.018 |
| MIP‐1β | 0.018 | 0.009 | 4.137 | .042* | 1.018 | 1.001‐1.036 |
| IL‐17 | 0.127 | 0.056 | 5.100 | .024* | 1.136 | 1.017‐1.269 |
| TNF‐α | −0.002 | 0.005 | 0.213 | .644 | 0.998 | 0.987‐1.008 |
| IL‐10 | −0.001 | 0.001 | 0.963 | .326 | 0.999 | 0.998‐1.001 |
| IL‐12p70 | −0.027 | 0.019 | 1.971 | .160 | 0.973 | 0.937‐1.011 |
Abbreviations: CI, confidence interval; OR, odds ratio; SE, standard error. * p<0.05